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magnetic resonance spectroscopy (Brown et al., 2004) . Hippocampal and amygdala atrophy has also been found in adults and children with elevated levels of endogenous glucocorticoids due to Cushing's disease (Merke et al., 2005; Patil et al., 2007) . Moreover, magnetic resonance spectroscopy studies in cured Cushing's disease patients revealed lower hippocampal N-acetyl aspartate and higher glutamate and glutamine levels suggestive of decreased neuronal density and increased glial proliferation (Resmini et al., 2013) .
While most studies investigated the impact of glucocorticoids on limbic structures, glucocorticoid treatment may impact other subcortical brain structures as well (Cao- Lei et al., 2013) . Notably, exposure to glucocorticoids in the neonatal period has recently been associated with smaller white matter, putamen, caudate nucleus, and globus pallidus volumes in adolescents born extremely premature (< 28 weeks), while differences in hippocampus or amygdala volumes were not observed (Cheong et al., 2014) .
In contrast to pre-and perinatal glucocorticoid exposure, studies investigating the long-term effects of exogenous glucocorticoid exposure later in childhood are sparse. This is despite the widespread use of glucocorticoids in the treatment of multiple pediatric diseases (Damsted et al., 2011) , and the fact that the brain continues to mature throughout childhood and adolescence as evidenced by in revealed that subcortical grey matter structures undergo developmental changes, as indexed by decreasing mean diffusivity (MD) (Lebel et al., 2008) . MD reflects the magnitude of water diffusion and is negative proportional to the amount of cell membranes and cellular structures (Beaulieu, 2002) . Notably, caudate nucleus MD has been reported to decrease well into adulthood, while putamen and globus pallidus MD appear to level off to adult levels in late adolescence (Lebel et al., 2008) . Thus, both volumetric and microstructural maturation occurs in subcortical regions during childhood and adolescence, which could potentially be affected by glucocorticoid exposure in this period of life.
The present study aimed to investigate the possible long-term effects of previous glucocorticoid treatment during childhood on the volume and microstructure of subcortical grey matter structures.
To this end, we compared child and adolescent patients, previously treated with glucocorticoids for
nephrotic syndrome or rheumatic disease, with healthy controls. We included these two different extra-cerebral pediatric diseases with the aim to control for potential disease-related effects. In previous work, we observed that these patients had lower verbal intellectual abilities (Holm et al., 2015) and smaller total brain volumes as compared to healthy controls (Holm et al., 2018) .
Furthermore, the children treated with glucocorticoid showed sex-dependent differences in endogenous cortisol profiles compared to healthy controls, with girls having higher cortisol awakening response (CAR) and boys having higher cortisol levels during the day (Vestergaard et al., 2017) . In the present study, our primary hypothesis was that patients, as compared to healthy controls, would have smaller hippocampal and amygdala volumes independent of differences in total brain volume. Secondary, we expected that patients would differ from controls in hippocampal and amygdala MD. Furthermore, we examined if patients differed from controls in putamen, caudate nucleus, or nucleus accumbens volume or MD. Finally, within patients we examined for possible doses-response associations between glucocorticoid treatment variables and subcortical brain structure volume or MD.
Material and methods
The participants in the present study are the same as in our recent study investigating the effects on glucocorticoid treatment on global structural brain measures (Holm et al., 2018) . Therefore, if identical, information on participants, clinical characteristics and background variables is presented between quotation marks followed by the reference to the previous article.
Participants
"A total of 30 children and adolescents previously treated with glucocorticoid because of either rheumatic disease or nephrotic syndrome, recruited from outpatient pediatric clinics, and 30 matched healthy controls, recruited from public schools, were included in the present study. Patient and control groups were matched on average age, gender, and parent education. The patients were between 7.0 and 16.1 years of age and consisted of 8 boys and 22 girls. The controls were between 7.0 and 15.6 years of age and consisted of 11 boys and 19 girls. The subjects were part of a larger cohort, which has been described in detail elsewhere (Holm et al., 2018) . Of the initial thirty-eight included patients, seven did not complete MRI scanning and one was excluded because of poor image quality due to motion artefacts. Thus, 30 patients with good-quality T1-weighted scans were included in the current study. Of the initially forty-two included healthy controls, five participants
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did not complete scanning and one control was excluded because of motion artefacts. Thus, goodquality scans were available for 36 healthy controls. To ensure that group averages for included patients were matched to controls on age, gender, and parent education, we excluded five boys and one girl with a mean age of 11.8 years and mean parental education of 17.1 years. Exclusion was done blinded to the MRI data and before any processing of MRI images or statistical analyses.
There were no significant differences in age, gender, or parental education between the initial included subjects and the subjects with good-quality MRI scan (all P values ≥ 0.30).
Only children and adolescents without neurological or psychiatric diseases or preterm birth were included. Controls were required to be healthy and without previous systemic glucocorticoid treatment. Only patients without current glucocorticoid treatment at the time of the study were 
Clinical characteristics
"Patients' medical charts were reviewed, and diagnosis and glucocorticoid treatment data were collected" (Holm et al., 2018) . "The study included 11 patients with nephrotic syndrome and 19
with rheumatic disease. The group of children with nephrotic syndrome included idiopathic nephrotic syndrome (n = 5), nephrotic syndrome associated with Henoch-ch nlein purpura (n = 4), and nephrotic syndrome associated with glomerulonephritis (n = 2). The group of children with rheumatic disease included systemic juvenile idiopathic arthritis (n = 1), polyarticular juvenile idiopathic arthritis (n = 3), oligoarticular juvenile idiopathic arthritis (n = 8), enthesitis-related juvenile idiopathic arthritis (n = 2), juvenile dermatomyositis (n = 3), mixed connective tissue disease (n=1), and systemic lupus erythematosus (n = 1)." (Holm et al., 2018) . Treatment variables are presented in Table 3 . "The primary treatment variable was cumulative prednisolone equivalent glucocorticoid dose (mg/kg). In addition, median daily dose (mg/kg/day), median treatment age, and time since treatment (i.e., time elapsed from treatment termination to assessment) were registered. Glucocorticoids were administered orally. However, five patients (one with nephrotic syndrome and four with rheumatic disease) received intravenous glucocorticoid high-dose therapy (pulse therapy) in addition to oral glucocorticoid treatment, which constituted between 36 and 64% of their cumulative dose" (Holm et al., 2018) . Twelve patients received non-glucocorticoid A C C E P T E D M A N U S C R I P T treatment at the time of assessment, which included TNF-α-inhibitors (n = 7), methotrexate (n = 3), anti-hypertensive drugs (n = 2), interleukin-1-inhibitor (n = 1), and non-steroid anti-inflammatory drugs (n = 1).
Background variables
"The assessment of background and cognitive variables are described in detail elsewhere (Holm et al., 2015) . Height, weight, head circumference, and pubertal development (Tanner staging) were measured. Current and previous physical activity, stressful life events, and behavioral problems were assessed by questionnaires" (Holm et al., 2018 
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A C C E P T E D M A N U S C R I P T posterior commissure line. All images were inspected for quality. All T1-weighted images were evaluated by a neuroradiologist and deemed without clinical pathology.
Image preprocessing

Preprocessing of T1-weighted images
T1-weighted images were processed using the VBM5.1 toolbox implemented in SPM8
(www.fil.ion.ucl.ac.uk/spm/software/spm8) running in Matlab R2013b. Initially, images were gradient unwarped to correct for non-linear spatial distortions in the scanner gradients (Jovicich et al., 2006) . After a 6 parameter rigid transformation to MNI-space, grey and white matter and CSF were segmented with VBM5.1 using default settings and the Hidden Markov Random Field method (Cuadra et al., 2005) . A brain mask generated using the graph-cut mask function was applied to the segmented tissue images to remove extra-cerebral tissue voxels. Tissue segmentations were visually inspected to ensure quality before warping the grey and white matter images with DARTEL (Diffeomorphic Anatomic Registration Through Exponentiated Lie algebra) to achieve highdimensional inter-individual alignment (Ashburner, 2007) . Subsequently, the individual DARTEL deformation flow fields were applied to individual masked brain tissue images in order to bring them into a common "DARTEL" space.
Pre-processing of diffusion weighted images
DW images were pre-processed using pipelines implemented in Matlab, using SPM8 routines as 
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Fractional anisotropy (FA) and mean diffusivity (MD) images were calculated. MD was calculated as the mean of diffusivities along three perpendicular axes (λ 1 , λ 2 , λ 3 ) (Basser and Jones, 2002) . FA images were used to calculate the best possible (non-linear) registration between MD images and individual T1-weighted anatomical images as part of the procedure to extract individual ROI MD (see below).
Grey matter regions-of-interest
Participants' T1-weighted images were warped into "DARTEL" space using individual DARTEL flow fields. Next, resulting images were averaged to create a T1-weighted study template, on which grey matter regions-of-interest (ROIs) were delineated using FSLView (www.fsl.fmrib.ox.ac.uk/fsl/fslview). Using the inverse DARTEL flow fields ROIs were transformed into each individual's T1-weighted image native space and edited to ensure their fit while blinded to subject identity.
The left and right hippocampi and amygdalae were drawn using previously described guidelines To extract individual ROI MD, we used the following procedure to minimize white matter and CSF partial volume effects and maximizing sampling within grey matter tissue. Firstly, ROIs were eroded using a 1 mm Gaussian kernel, thereby excluding an approximately one-voxel thick layer from the outer border of the ROI. Secondly, for each individual the FA image was warped to the T1-weighted image in native space using the linear FLIRT and non-linear FNIRT registration algorithms in FSL. The resulting deformation fields were then applied to the MD images and the anatomical fit was visually inspected. Thirdly, using the inverse deformation the eroded ROIs residing in T1-weighted native space were transformed to diffusion-weighted native image space using tri-linear interpolation and binarized using a threshold of 0.5. The anatomical match was ACCEPTED MANUSCRIPT
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visually inspected. Fourthly, the binary ROIs were multiplied by the participant's perpendicular diffusivity image, and then thresholded at a perpendicular diffusivity of less than 0.0011, in order to exclude any remaining CSF partial volume voxels. Finally, mean MD values were extracted from the final ROIs for each subject. To estimate individual global MD within grey and white matter, mean MD was calculated within a whole brain mask created by thresholding individual perpendicular diffusivity images < 0.0009 to exclude CSF and CSF partial volume voxels.
To obtain estimates of total brain volume (TBV) for use in the statistical analyses, we used the automated calculated TBV within FreeSurfer, a freely available software package for structural and functional image analyses (https://surfer.nmr.mgh.harvard.edu). Processing of individual T1-weighted images with FreeSurfer followed standard procedures and is described in detail elsewhere (Holm et al., 2018) . The pial and grey-white matter surfaces generated by FreeSurfer were visually inspected and corrected following standard guidelines where necessary. The TBV included supraand infratentorial volumes of grey and white matter, while ventricles, brain-stem and choroid plexus were excluded (www.freesurfer.net/fswiki/MorphometryStats).
Statistics
The statistical analyses for demographic and background variables are largely the same as in our previous work (Holm et al., 2018) . Therefore, wherever information is the same it is presented between quotation marks, followed by the reference to the article in which the information can be found. SPSS 20 (SPSS, IBM Corp., USA) was used for statistical analyses.
Demographic and background variables
"A χ2-test tested for possible gender differences. The Shapiro-Wilk test was used to test whether continuous variable distributions deviated from a normal distribution. Independent samples t-tests tested for group differences in normally distributed variables, including age and parent education.
Group differences in the background, behavioral, and cognitive variables, height, weight, head circumference, verbal comprehension index (VCI), perceptual organization index, Tanner stage, physical activity, stressful life events, behavioral problems, and pattern recognition memory were evaluated using multiple linear regression with age and gender as control variables. The lifetime stressful life event (SLE) questionnaire includes two statements regarding somatic disease (i.e., "my child had a medical diagnosis" and "my child was severely ill or injured"), which patients and controls are expected to differ on. Therefore, we report stressful life events with and without these
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disease-related questions. Within patients, Mann-Whitney U-tests tested for potential gender-and disease-group differences in treatment variables" (Holm et al., 2018) . CAR and the daily cortisol levels were evaluated using multiple linear regression with age and gender as control variables.
Subcortical brain measures
Potential differences between patients and controls in ROI volume or ROI MD were evaluated using multiple linear regression analyses. All assumptions for linear regression were fulfilled.
Adjusted mean differences (AMD) are reported i.e. difference between groups in ROI volumes and ROI MD after controlling for all other predictors in the regression model.
Our primary hypothesis was that patients would have smaller left and right hippocampal and amygdala volumes compared to controls and that this difference would be independent of previously observed group differences in whole brain volume. Secondary, we expected that patients as compared to controls would differ in hippocampus and amygdala MD. ROI volume or ROI MD were used as dependent variables, and group (controls versus patients), age and gender were used as independent prediction variables. The anatomic specificity of observed associations was assessed by adding TBV in models predicting ROI volume, and global MD in models predicting ROI MD.
Hippocampus and amygdala volume and MD were analyzed unilaterally since study findings suggest lateralized relations between glucocorticoids and limbic structures (Cerqueira et al., 2008;
Madsen et al., 2012). Bilateral measures were used for testing group differences in putamen, caudate nucleus or nucleus accumbens volume or MD. Finally, we explored group by gender interactions to evaluate potential gender specific differences between patients and controls controlling for age and global measures. Pertinent to a significant interaction, we tested group differences for each gender separately. 
Associations with glucocorticoid treatment variables
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dose by median treatment age interaction tested whether the effect of glucocorticoid treatment differed depending on the age at which children received treatment.
Planned follow-up analyses
To evaluate if observed group differences were present in each of the disease groups, we contrasted rheumatic disease patients and nephrotic syndrome patients separately with healthy controls, controlling for age, gender, and TBV or global MD. For the primary hypotheses concerning left and right hippocampal and amygdala volume, we used a
Bonferroni corrected p-value of 0.013 (α = 0.05/4). Since this, to our knowledge, is the first study to investigate the possible long-term impact of glucocorticoid treatment during childhood on subcortical grey matter structures, we were interested to identify potential group differences and associations that can be tested in future studies. Therefore, in all subsequent analyses we considered effects with p-values lower than 0.05 of interest.
Results
Results on demographic data and background variables (except CAR and daily cortisol levels) are the same as presented in our previous article on global brain measures (Holm et al., 2018) . These results will be presented between quotation marks followed by the reference to the previous article and the page at which the information can be found.
Missing data
There was missing data for measures of CAR and daily cortisol level (one female patient with rheumatic disease), current physical activity (two female patients with rheumatic disease and one male control), previous physical activity (two female patients with rheumatic disease) and DWI scans (two controls: one boy, one girl, and three female patients with rheumatic disease).
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Demographic data and background variables
Demographic variables are presented in Table 1 . Age, gender, and parental education were not significantly different between controls and all patients or between controls and the separate disease groups. Furthermore, comparisons between the two patient groups revealed no significant differences in age (t = 0.12, p = 0.91), gender (p=0.08), or parent education (t = 0.54, p = 0.59).
" 
Treatment variables
Treatment variables and the results of statistical analyses comparing children with nephrotic syndrome with children with rheumatic disease and comparing boys and girls, are presented in Table 2 . Children with nephrotic syndrome received significant higher cumulative dose and median daily dose of glucocorticoids than children with rheumatic disease. Disease groups did not differ on any of the other treatment variables. Additionally, patient boys had significant longer time since treatment and received higher median daily doses than patient girls. Boys and girls did not differ on the remaining treatment variables. Disease group by gender interaction effects were absent (pvalues > 0.11).
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Subcortical brain measures
Measures of ROI volume and ROI MD for controls and patients and patient groups separately are presented in Table 3 . Results of multiple regression analyses of volume and MD are presented in Table 4 and Table 5 , respectively.
Primary analyses
Hippocampal and amygdala volume
Patients had smaller right hippocampal volumes compared to controls (AMD = -153. 
Secondary analyses
Hippocampal and amygdala MD
Patients had lower right hippocampal MD as compared to controls (AMD = -9. 
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Explorative analyses
Putamen, caudate nucleus and nucleus accumbens volume
Patients had significantly smaller putamen volume as compared to controls (AMD = -675 mm 3 ; 95% CI = -1091 --259) and this group difference remained after controlling for TBV (AMD = -353 mm 3 ; 95% CI = -662 --44; Figure 2B ). We did not find a significant group by gender interaction (β = 0.04, p = 0.69).
Patients and controls did not significantly differ in caudate nucleus or nucleus accumbens volumes with or without correction for TBV. Likewise, no significant group by gender interactions were observed (caudate nucleus: β = -0.07, p = 0.46; nucleus accumbens: β = 0.02, p = 0.90).
Putamen, caudate nucleus and nucleus accumbens MD
Patients and controls did not significantly differ in putamen, caudate nucleus or nucleus accumbens MD. We did not find any significant group by gender interactions (putamen: β = 0.004, p = 0.97, caudate nucleus: β = 0.05, p = 0.63; nucleus accumbens: β = 0.12, p = 0.38).
Planned follow-up analyses
Right hippocampal MD
Associations with glucocorticoid treatment variables within patients
Within patients, right hippocampal MD was not significantly associated with cumulative dose (β = -0.27, p = 0.17). However, we found a positive association between right hippocampal MD and the time elapsed since termination of treatment (β = 0.57, p = 0.016, Figure 3A) , suggesting that the longer time since patients received glucocorticoids the more they resembled the control group.
Median daily dose, treatment duration, median treatment age, or the cumulative dose by median treatment age interaction were not significantly associated with right hippocampal MD (p's > 0.1).
Excluding the five individuals who received pulse therapy did not affect the above findings.
Comparing disease groups separately to healthy controls
Follow-up analyses investigating for group differences in right hippocampal MD for each disease group separately, controlling for age, gender and global MD, revealed that children with nephrotic 
Associations with verbal comprehension index
VCI was still significant lower in patients than controls after controlling for right hippocampal MD, 
Putamen volume
Associations with glucocorticoid treatment variables within patients
Putamen volume was not associated with cumulative dose (β = -0.19, p = 0.14), median daily dose, treatment duration, nor time since treatment (p's > 0.26). However, putamen volume was negatively associated with median treatment age (β = -0.31, p = 0.03; Figure 3B ). Putamen volume was not associated with cumulative dose by median treatment age (p > 0.7). Excluding individuals who received pulse therapy did not affect the above findings.
Comparing disease groups separately to healthy controls
Analyses revealed that the observed group difference in putamen volume was present in children Furthermore, the observed negative association between median treatment age and putamen volume was present in the children with rheumatic disease (β = -0.44, p = 0.015), while absent in children with nephrotic disease (β = 0.08, p = 0.84).
Associations with verbal comprehension index
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VCI was still significantly lower in patients than controls after controlling for putamen volume, and there was no apparent relationship between putamen volume and VCI (Group: β = -0. 48 
Discussion
To the best of our knowledge the present study is the first to describe a possible relationship between extra-cerebral diseases treated with glucocorticoids during childhood and adolescence, and differences in limbic and striatal grey matter structure volume and microstructure in children and adolescents. Contrary to our expectations, patients did not differ from controls in hippocampal or amygdala volumes, as the initially observed smaller right hippocampal volumes in patients as compared to healthy did not survive correction for multiple comparisons. Furthermore, exploring if the uncorrected group difference showed anatomical specificity, by correcting for TBV, revealed this likely not to be the case. Nevertheless, patients displayed lower right hippocampal MD than healthy controls, a difference that remained when accounting for whole brain MD. Although, lower right hippocampal MD was most prominent in children with nephrotic syndrome, who had received the highest cumulative and median daily glucocorticoid dose, possible disease specific effects cannot be excluded. Interestingly, we found that the right hippocampal MD in patients reached values comparable to those of healthy controls the more time had elapsed since glucocorticoid treatment. This relationship was observed in both disease groups separately. Patients did not differ from controls in amygdalae MD. Finally, putamen volume was smaller in patients as compared to controls, a difference that was mainly driven by the children with rheumatic disease. Notably, putamen volume was smaller the older the children were when receiving glucocorticoid treatment.
The general lack of studies investigating the effect of glucocorticoid treatment in childhood and adolescence for extra-cerebral diseases on limbic and striatal grey matter structures makes it difficult to assess the validity and significance of our findings. Our observation of smaller right hippocampal volumes in patients as compared to healthy controls did not survive correction for multiple comparisons. Exploring if this difference might show anatomical specificity by correcting for TBV, revealed that this likely was not the case. The latter would align with our previous finding in the same cohort with patients displaying significant smaller total brain volumes as compared to healthy controls (Holm et al., 2018) . Overall, our failure to observe hippocampal volume differences may be rooted in e.g. insufficient statistical power, lack of anatomical specificity, and/or A C C E P T E D M A N U S C R I P T a lack of signal in hippocampal volume due to relative low median daily glucocorticoid doses in combination with relative lengthy time since treatment. Nevertheless, our observation warrants further investigation given the available evidence suggesting that postnatal treatment with glucocorticoids affects hippocampal volume. In a study of preterm born children (gestational age at birth < 30 weeks), scanned at term-equivalent age ( years after exposure (Cheong et al., 2014) . Moreover, a study in preterm fetal sheep found that exposure to glucocorticoids aggravated the neuronal injury following asphyxia in the hippocampus, but also in the putamen (Koome et al., 2013) . However, smaller putamen volumes were most prominent in children with rheumatic diseases and the observed negative association between the median treatment age and putamen volume was absent in the children with nephrotic disorder.
Since the children with rheumatic disease received lower cumulative and median daily dose of glucocorticoids than the children with nephrotic syndrome, our findings suggest that the observed smaller putamen volume may more likely be a disease-specific effect rather than due to the glucocorticoid treatment by itself. Furthermore, we may have lacked the statistical power to find smaller putamen volumes in patients with nephrotic syndrome given the lower number of patients
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with nephrotic syndrome in our study. Finally, it might also be that potential disease specific findings are, at least partly, reflective of an uneven gender distribution in the two disease groups, with more girls among the children with rheumatic disease.
Overall, the present study is limited due to the relatively small sample sizes, as well as an uneven gender distribution in the two disease groups, with more girls among the children with rheumatic disease. Thus, we cannot exclude if the lack of specific hippocampal volume differences is due to a lack of statistical power. Moreover, by the very nature of our cross-sectional design we are not able to infer causality of previous glucocorticoid treatment, nor are we able to infer possible disease related mechanism. Unfortunately, this inability to differentiate disease-specific effects from glucocorticoid treatment effects befalls most cross-sectional studies in patient populations.
Furthermore, some participants also received other drugs such as TNF-inhibitors or methotrexate.
The most dominant non-glucocorticoid treatment at the time of assessment concerned TNF-inhibitors. Interestingly, these have recently been found to prevent pharmacological neurotoxicity in the developing brain in rodents (Chen et al., 2016) . Unfortunately, given the small number of patients receiving additional drug treatment, we were not able to address this issue in the current study, and therefore cannot exclude the possibility that additional treatments may have influenced our results. Finally, an ideal control group would consist of patients with comparable disease histories, who had not been treated with glucocorticoids. However, it not possible to identify such a disease control group due to differences in disease mechanisms, course of illness, illness severity, and treatment made. By including the two non-cerebral disease groups, we reasoned that effects common to both groups, specifically associations with glucocorticoid treatment variables, would be more reflective of glucocorticoid treatment than disease specific effects.
In conclusion, we revealed for the first time that extra-cerebral diseases during childhood treated with glucocorticoids may be associated with reduced subcortical grey matter volumes and lower right hippocampal mean diffusivity later in life. While our results should be considered preliminary, they warrant replication and elaboration in larger, preferably prospective and longitudinal studies.
Such studies would also allow disentangling disease-specific effects from glucocorticoid treatment effects.
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Figure 1 Regions-of-interest
Regions-of-interest overlaid on the average of warped T1-weighted images. 
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Highlights  Previous glucocorticoid treatment linked to lower right hippocampal mean diffusivity  This effect was most prominent in children and adolescents with nephrotic syndrome  Right hippocampal mean diffusivity normalised with longer time since treatment  Smaller putamen volumes in patients were driven by children with rheumatic disease
